FDA.reportPublic FDA data

Conexxence 60 MG per 1 ML Prefilled Syringe

RxCUI
2717538
RxNorm name
Conexxence 60 MG per 1 ML Prefilled Syringe
Display name
Conexxence 60 MG per 1 ML Prefilled Syringe
Full name
Conexxence 60 MG per 1 ML Prefilled Syringe
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:54

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761398Conexxencedenosumab-bnht351(k) InterchangeableRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CONEXXENCEDENOSUMABFresenius Kabi USA, LLC39a0a789-778f-4695-b3a9-61643e6396cd2025-12-15Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2717538

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
39a0a789-778f-4695-b3a9-61643e6396cdConexxence 60 MG in 1 ML Prefilled Syringe [PSN] · 1 ML denosumab-bnht 60 MG/ML Prefilled Syringe [Conexxence] [SBD] · Conexxence 60 MG per 1 ML Prefilled Syringe [SY] · Conexxence 60 MG/ML per 1 ML Prefilled Syringe [SY]43These highlights do not include all the information needed to use CONEXXENCE safely and effectively. See full prescribing information for CONEXXENCE. CONEXXENCE (denosumab-bnht) injection, for subcutaneous use Initial U.S. Approval: 2025 CONEXXENCE (denosumab-bnht) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differen20251215